Burden Of Influenza

According to the CDC, the flu places a significant burden on the health and economy of the United States1,2

plus icon

228 million*

flu-related illnesses

Occurred over 8 seasons between 2010 and 20181

doctors icon

106 million*

flu-related medical visits

Occurred over 8 seasons between 2010 and 20181

patient icon

3.79 million*

patients hospitalized

Occurred over 8 seasons between 2010 and 20181

calendar icon

17 million*

missed work days

annually due to flu2

*Estimated number.


The impact of flu varies each year but remains significant.1

Annual CDC flu vaccination goals have not been reached

The CDC’s healthy people 2020 objective for annual flu vaccination rate in children 6 months-17 years is 70%3

Flu vaccine coverage rates for children by age group4
Age Group
(%) Early Estimate 2018/19 Vaccinations
6 months - 4 years*
57.4
5-12 years
46.0
13-17 years
35.1

*FLUMIST QUADRIVALENT is indicated for patients 2-49 years of age.

Current early season estimate for 2018-2019 vaccinations through mid-November 2018.

In the 2018-2019 season.

child population icon

Approximately 54% of this child population went unvaccinated


The CDC states that overall vaccination coverage remains suboptimal5

flu icon

Additional options for vaccination of children, including use of noninjectable vaccines such as LAIV4, might provide a means to improve coverage, particularly in school-based settings.5

CDC=Centers for Disease Control and Prevention, LAIV=Live Attenuated Influenza Vaccine.

IMPORTANT SAFETY INFORMATION


  • FLUMIST QUADRIVALENT is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) to any vaccine component, including egg protein, or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy
  • In clinical trials, the risks of hospitalization and wheezing were increased in children <24 months of age who received trivalent FluMist
  • Children <5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following FLUMIST QUADRIVALENT administration. FLUMIST QUADRIVALENT has not been studied in persons with severe asthma or active wheezing
  • If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST QUADRIVALENT should be based on careful consideration of the potential benefits and risks
  • FLUMIST QUADRIVALENT has not been studied in immunocompromised persons
  • The safety of FLUMIST QUADRIVALENT in individuals with underlying medical conditions predisposing them to wild-type influenza infection complications has not been established
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine
  • FLUMIST QUADRIVALENT may not protect all individuals receiving the vaccine
  • The most common solicited adverse reactions (occurring ≥10% in vaccine recipients and at least 5% greater than in placebo) reported were runny nose or nasal congestion in persons 2-49 years, fever >100°F in children 2-6 years, and sore throat in adults 18-49 years. Among children 2-17 years who received FLUMIST QUADRIVALENT, 32% reported runny nose or nasal congestion and 7% reported fever >100°F. Among adults 18-49 years who received FLUMIST QUADRIVALENT, 44% reported runny nose or nasal congestion and 19% reported sore throat

FLUMIST QUADRIVALENT is a vaccine indicated for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUMIST QUADRIVALENT is for intranasal administration only.

Please see full Prescribing Information for FLUMIST QUADRIVALENT, including Patient Information.

You may report side effects related to AstraZeneca products by clicking here.